Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GSKGLAXF -1.16%67 Future 3-5Y EPS without NRI Growth Rate is 5.71 as of Sep. 04, 2026. GuruFocus rates GLAXF with a GF Score™ of 67/100 and a GF Value™ of $21.87 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 230 Drug Manufacturers companies, GSK ranks worse than 92.17% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, GSK's Future 3-5Y EPS without NRI Growth Rate is 5.71.
GSK (OTCPK:GLAXF) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
GSK Future 3-5Y EPS without NRI Growth Rate Related Terms
GLAXF vs LLY, JNJ, ABBV: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - General subindustry, GSK's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK Future 3-5Y EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where GSK's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 5.71 mean?
GSK (GLAXF) has a Future 3-5Y EPS without NRI Growth Rate of 5.71 as of Sep. 04, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for GSK and its competitors. According to the industry distribution chart, GSK ranks #212 out of 230 companies in the Drug Manufacturers industry, placing it in the top 92.2%.
Is GSK's Future 3-5Y EPS without NRI Growth Rate too high?
GSK's current Future 3-5Y EPS without NRI Growth Rate is 5.71. The Drug Manufacturers industry median Future 3-5Y EPS without NRI Growth Rate is 16.67. GSK's value of 5.71 is 65.7% below this industry median. Based on the distribution chart, GSK ranks #212 out of 230 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, GSK has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Future 3-5Y EPS without NRI Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #212 out of 230 companies for Future 3-5Y EPS without NRI Growth Rate. This places GSK in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 16.67. GSK's value of 5.71 is 65.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Drug Manufacturers company?
The median Future 3-5Y EPS without NRI Growth Rate among Drug Manufacturers companies is 16.67, based on 230 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current Future 3-5Y EPS without NRI Growth Rate of 5.71 is 65.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for GSK and its competitors. For the Drug Manufacturers industry, the median Future 3-5Y EPS without NRI Growth Rate is 16.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current Future 3-5Y EPS without NRI Growth Rate is 5.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.87, compared to a current price of $25.21 — trading 15.2% above its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 5.71 and 65.7% below the Drug Manufacturers industry median of 16.67. GSK's overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For GSK (GLAXF), the current Future 3-5Y EPS without NRI Growth Rate is 5.71 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $25.21 is trading 15.2% above its estimated GF Value™ of $21.87.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
Future 3-5Y EPS without NRI Growth Rate: 5.71
GF Value™: $21.87 vs. price of $25.21 (15.2% above fair value)
Industry Position: 65.7% below the Drug Manufacturers median (#212 of 230)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
67GF Score
Get the complete analysis for GLAXF
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
